Samsung Biologics decided to separate its contract development and manufacturing (CDMO) business through a human partitioning, resulting in the suspension of stock transactions until 9:30 a.m. on the 22nd.
The Korea Exchange's securities market division noted that this decision came after Samsung Biologics announced its company partitioning.
After the human partitioning, Samsung Biologics will be divided into Samsung Biologics and a newly established company, Samsung Ephis Holdings (tentative name). Samsung Ephis Holdings will manage subsidiaries including Samsung Bioepis and engage in new investment-related business.
The partitioning ratio is 0.6503913 for Samsung Biologics to 0.3496087 for Samsung Ephis Holdings. Shareholders who previously held 100 shares of Samsung Biologics will receive 65 shares of Samsung Biologics and 35 shares of Samsung Ephis Holdings.
Samsung Biologics plans to list partitioned new shares on May 22, 2025, following an extraordinary shareholders' meeting on September 16.